9PL

(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one

Find entries where: 9PL

is present as a standalone ligand in 4 entries

Find related ligands:

Chemical Component Summary
Name	(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
Synonyms	PILOCARPINE
Identifiers	(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
Formula	C₁₁ H₁₆ N₂ O₂
Molecular Weight	208.257
Type	NON-POLYMER
Isomeric SMILES	CC[C@H]1[C@H](COC1=O)Cc2cncn2C
InChI	InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1
InChIKey	QCHFTSOMWOSFHM-WPRPVWTQSA-N

Chemical Details
Formal Charge	0
Atom Count	31
Chiral Atom Count	2
Bond Count	32
Aromatic Bond Count	5

Drug Info: DrugBank

DrugBank ID	DB01085
Name	Pilocarpine
Groups	approved investigational
Description	A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.[A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by pilocarpine dates back to 1875.[A262041]
Synonyms	Pilocarpine pamoate Pilocarpina Pilocarpine OCUCARPINE SPERSACARPINE 2(3H)-FURANONE, 3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-, (3S-CIS)- SYNCARPINE Pilocarpine nitrate Pilocarpine hydrochloride PILOKARPIN
Brand Names	Salagen Pilocarpine Hydrochloride Ophthalmic Solution 4% USP PMS-pilocarpine 0.5% Betoptic Pilo E-pilo-6 Oph Soln Jamp Pilocarpine Miocarpine Oph Soln 6% Odan-pilocarpine Isopto Carpine 0.5% pilocarpine Hydrochloride Pilocarpine Hydrchloride PMS-pilocarpine 4% Pilocarpine 1% Pilocarpine Hydrochloride Tablets, USP Pilocarpine Hydrochloride Tablets Isopto Carpine E-pilo 1 Ophthalmic Solution Miocarpine Oph Soln 2% Timpilo 4 Miocarpine Ophthalmic Solution 4% Miocarpine Ophthalmic Solution 2% Pilopine Hs 4% Miocarpine Oph Soln 4% R.O. -carpine 1% R.O.-carpine 4% E-pilo 2 Ophthalmic Solution Pilocarpine Hydrochloride 1% - Liq Oph Pilopine Hs Miocarpine Ophthalmic Solution 1% E-pilo-4 Oph Soln E-pilo-2 Oph Soln Pilocarpine 6% Pilocarpine Hydrochloride 4% - Liq Oph Minims Pilocarpine Nitrate 4% Pilocarpine Hydrochloride 2% - Liq Oph Isopto Carpine Liq 6% Pilocarpine 2% Minims Pilocarpine Nitrate Miocarpine Oph Soln 1% Pilocarpine hydrochloride Vuity Betoptic/pilo Pilocarpine Hydrochloride PMS-pilocarpine 2% R.O.-carpine 2% Pilocarpine 4% Ocusert Pilo 40 Pilocarpine Miocarpine Ophthalmic Solution 6% Ocusert Pilo 20 Pilocarpine Hydrochloride Ophthalmic Solution 1% USP Pilocarpine Hydrochloride Ophthalmic Solution 2% USP E-pilo 6 Ophthalmic Solution E-pilo 4 Ophthalmic Solution M-pilocarpine PMS-pilocarpine 1% PMS-pilocarpine 6% E-pilo-1 Oph Soln Timpilo 2
Indication	Pilocarpine oral tablets are indicated for the treatment of dry mouth caused by Sjogren's Syndrome or radiotherapy for cancer of the head and neck.[L48566] Pilocarpine ophthalmic formulations are used to treat presbyopia in adults,[L48556, L48631] reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, manage acute angle-closure glaucoma, prevent postoperative elevated IOP associated with laser surgery, and induce miosis.[L48561]
Categories	Alkaloids Antiglaucoma Preparations and Miotics Autonomic Agents Cholinergic Agents Cholinergic Agonists Cholinergic Receptor Agonist Cytochrome P-450 CYP2A6 Inhibitors Cytochrome P-450 CYP2A6 Inhibitors (strong) Cytochrome P-450 CYP2A6 Substrates Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Miotics Muscarinic Agonists Nervous System Neurotransmitter Agents Ophthalmologicals Parasympathomemetic (Cholinergic) Agents Parasympathomimetics Peripheral Nervous System Agents Sensory Organs
ATC-Code	N07AX01 S01EB01 S01EB51
CAS number	92-13-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Muscarinic acetylcholine receptor M3	MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFS...	unknown	agonist
Muscarinic acetylcholine receptor M1	MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISF...	unknown	agonist
Muscarinic acetylcholine receptor M2	MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKV...	unknown	agonist
Muscarinic acetylcholine receptor M4	MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGN...	unknown	partial agonist
Muscarinic acetylcholine receptor M5	MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVL...	unknown	agonist
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	inhibitor
Cytochrome P450 2A6	MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLN...	unknown	substrate,inhibitor
Serum paraoxonase/arylesterase 1	MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIET...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682